Belgium-based biotechnology company ThromboGenics has reported results from the Phase IIIb OASIS study of JETREA (ocriplasmin) in patients with symptomatic vitreomacular adhesion (sVMA).

JETREA is the company's lead product and is a proteolytic enzyme developed to treat sVMA.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The randomised, sham-controlled, double-masked Phase IIIb OASIS trial has been conducted over a period of two years.

It was designed to determine the long-term safety and efficacy offered by JETREA to patients suffering from sVMA who were administered with JETREA through an injection.

"We are pleased that the positive results from this Phase IIIb, randomised controlled trial have now been published in the prestigious AAO Journal Ophthalmology."

sVMA describes a condition whereby the separation of the central gel vitreous in the eye is not completely detached from the retina.

See Also:

Small portions of vitreous cling to the macula, which is the part of retina responsible to generate vision.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The data was published in the AAO Journal Ophthalmology and stated that the trial had exhibited the long-term efficacy and safety of JETREA as it had resulted to improvement in symptoms indicative of sVMA.

ThromboGenics CEO Dr Patrik De Haes said: "We are pleased that the positive results from this Phase IIIb, randomised controlled trial have now been published in the prestigious AAO Journal Ophthalmology.

“We are confident that the OASIS data will provide very helpful guidance to the global retina community in their assessment of JETREA as an effective and safe treatment option for an important group of patients with symptomatic VMA."

The results of the study, along with its sub study, will be released at upcoming US and global retina specialists educational meetings.